Santaris Adds miR-33 to Its Pipeline Via Mass General Licensing Deal
March 03, 2011
Santaris Adds miR-33 to Its Pipeline Via Mass General Licensing Deal
The microRNA has been shown to suppress a protein important for the generation of high-density lipoprotein and for the removal of of cholesterol from peripheral tissues, according to the company.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - UNC Researchers Report New Details on Role of miR-122 in HCV
December 20, 2012 / Gene Silencing News - Rosetta Green Licenses microRNA from Iowa State
August 16, 2012 / Gene Silencing News - People in the News: Soren Tulstrup, Henrik Stage
May 31, 2012 / Gene Silencing News - With Positive Phase II Data on HCV Drug, Santaris Aims for Another Clinical Trial by the Summer
April 26, 2012 / Gene Silencing News